| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Rising Demand from Third-Party Diagnostic and Biotechnology Companies Drives CDMO Service ExpansionComprehensive CDMO services ...
Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company, announced today a marketing services arrangement with Henry Schein,...
- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation's Most Trusted Health Care Distributo...
Biomerica (NASDAQ:BMRA) reported $1.380 million in sales this quarter. This is a 23.63 percent decrease over sales of $1.807 mi...
New AI-enabled digital tool empowers patients to confidently manage IBS symptoms and avoid the trigger foods identified by inFo...
.